» Articles » PMID: 36855500

A Review on Clostridioides Difficile Testing and How to Approach Patients With Multiple Negative Tests: A Case Report

Overview
Journal Cureus
Date 2023 Mar 1
PMID 36855500
Authors
Affiliations
Soon will be listed here.
Abstract

() is an important nosocomial infection that is commonly associated with antibiotic use with pseudomembranous colitis being present in only 13% of cases. Disease severity ranges from asymptomatic carriers to severe complicated disease, based on clinical and laboratory findings. There is no single rapid FDA-approved test to diagnose infections (CDI) and diagnosis usually requires a multi-step diagnostic approach. testing usually begins with the toxin and glutamate dehydrogenase antigen screen (GDH). If testing is negative for either, then nucleic acid amplification testing (NAAT) is done to confirm the diagnosis. Endoscopic evaluation may be required in rare instances when there is a high clinical suspicion of disease with negative testing. Here, we present an interesting case of a patient with multiple negative toxin and GDH tests. Given the high index of clinical suspicion of CDI, the patient underwent a colonoscopy which revealed diffuse pseudomembranous colitis. The patient was then appropriately treated with oral vancomycin. We aim to shed light on the different testing modalities available to clinicians and the indications for doing a colonoscopy to delineate between false positive testing and active CDI.

Citing Articles

Pseudomembranous colitis and Parabacteroides distasonis bacteraemia: a rare clinical presentation.

Hsu C, Moore-Gillon C, Vithayathil M, Karim S Clin J Gastroenterol. 2024; 17(3):457-460.

PMID: 38483783 DOI: 10.1007/s12328-024-01939-6.

References
1.
Murad Y, Perez J, Ybazeta G, Mavin S, Lefebvre S, Weese J . False Negative Results in Clostridium difficile Testing. BMC Infect Dis. 2016; 16(1):430. PMC: 4992222. DOI: 10.1186/s12879-016-1741-6. View

2.
Arriola V, Tischendorf J, Musuuza J, Barker A, Rozelle J, Safdar N . Assessing the Risk of Hospital-Acquired Clostridium Difficile Infection With Proton Pump Inhibitor Use: A Meta-Analysis. Infect Control Hosp Epidemiol. 2016; 37(12):1408-1417. PMC: 5657489. DOI: 10.1017/ice.2016.194. View

3.
Kazanowski M, Smolarek S, Kinnarney F, Grzebieniak Z . Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review. Tech Coloproctol. 2013; 18(3):223-32. PMC: 3950610. DOI: 10.1007/s10151-013-1081-0. View

4.
Norris A, Shrestha N, Allison G, Keller S, Bhavan K, Zurlo J . 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy. Clin Infect Dis. 2018; 68(1):1-4. DOI: 10.1093/cid/ciy867. View

5.
Abt M, McKenney P, Pamer E . Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol. 2016; 14(10):609-20. PMC: 5109054. DOI: 10.1038/nrmicro.2016.108. View